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Synopsis 
 
Electrolyte disorders can result in life threatening complications. The kidneys are 
tasked with maintaining electrolyte homoeostasis, yet the low glomerular filtration 
rate of neonatal kidneys, tubular immaturity, and high extra-renal fluid losses 
contribute to an increased occurrence of electrolyte disorders in the newborn period. 
Understanding the physiological basis of renal electrolyte handling is critical for 
identification of underlying causes and initiation of proper treatment. 
Here we will review key aspects of renal physiology, the diagnostic work-up of 
disorders of plasma sodium and potassium and the appropriate treatment. In 
addition, we will review some inherited disorders associated with neonatal electrolyte 
disturbances that illuminate the physiology of renal electrolyte handling. 
 
 
Key words: electrolyte disorders, hyponatremia, hypernatremia, hypokalemia, 
hyperkalemia, newborn, renal physiology 
 
Key points: 
• Electrolyte homoeostasis is maintained by the kidneys 
• Disorders of plasma sodium commonly reflect disorders of water 
• Sodium handling by the kidneys is determined by volume homeostasis rather 
than plasma sodium 
• Volume (i.e. sodium) homeostasis and potassium homeostasis are 
interdependent 
• Low GFR and tubular immaturity contribute to an increased frequency of 
electrolyte abnormalities in the neonatal period 
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Introduction 
The evolution of life started in the sea, which contained a steady concentration of 
salts.  The function of living cells is thus critically dependent on a constant electrolyte 
composition and the evolution of life on land was only possible due to the 
development of kidneys, which provided this constant “internal milieu” 2. Disorders 
in the electrolyte composition of this milieu thus can have serious consequences and 
are associated with morbidity and mortality 3. Abnormalities of plasma sodium and 
potassium are a frequent occurrence in neonates and especially in the neonatal 
intensive care unit (NICU). In order to provide adequate treatment, it is important to 
understand the underlying problem and physiology 4. For instance, a common 
response to hyponatremia is to increase sodium supplementation. Yet, most patients 
with hyponatremia do not have a sodium deficiency, but water excess. Increasing 
sodium administration in these patients may correct the hyponatremia, but will result 
in volume overload, which has serious risks in the neonatal period, such as patent 
ductus arteriosus, bronchopulmonary dysplasia and necrotizing enterocolitis,5-7. 
We will review the physiology of renal water and electrolyte handling with respect to 
dysnatremias and dyskalemias in the context of the special circumstances of the 
transition from intra- to extrauterine life. In addition, we will discuss some rare 
inherited disorders associated with neonatal electrolyte abnormalities. 
 
Basics of renal water and electrolyte handling 
In an average adult (surface area 1.73m2) with a glomerular filtration rate (GFR) of 
100 ml/min, the kidneys produce 144 liters of primary filtrate a day. Assuming a 
sodium and potassium concentration of 140 and 4 mmol/l, respectively, these 144 
liters contain approximately 20000 mmol of sodium and 500 mmol of potassium. 
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Whilst the vast majority (60-80%) of this is reabsorbed isotonically in the proximal 
tubule, there is still a large volume of water, sodium and potassium delivered to the 
distal tubule, where decisions can then be made about either reabsorption or 
excretion. Urine osmolality can range from <50 to >1000 mosm/kg, so that, 
depending on intake and extrarenal losses, urine output can vary roughly between 500 
ml to 20 litre a day. Similarly, tubular sodium reabsorption can be adjusted so that 
sodium excretion may range from < 10 to >1000 mmol per day 8.  Potassium can even 
be secreted, so that potassium excretion may exceed the filtered amount 9. Thus, with 
normal kidney function, renal water, sodium and potassium excretion can be adjusted 
over a very wide range to provide homeostasis even under extreme circumstances. 
However, with decreased GFR, the ability of the kidneys to maintain volume and 
electrolyte homeostasis diminishes, so that abnormalities can occur more easily. 
 
The special circumstances of the neonatal kidney 
Whilst the same physiological principles apply to neonatal and adult kidneys, there 
are some important differences in the ability to maintain water and electrolyte 
homeostasis: 
• Neonatal kidneys have a low GFR: GFR measured by creatinine clearance in 
pre-term infants from 27-31 weeks of gestation without apparent kidney 
disease can be lower than 10 ml/min/1.73m2 in the first week of life and 
increases to only >15.5 ml/ min/1.73m2  by 4 weeks of life 10. 
• Urinary concentrating ability is not fully developed until about 1 year of age. 
In fact, all neonates have a degree of physiologic nephrogenic diabetes 
insipidus, so that maximal urine concentration may not exceed 300 mosm/kg, 
even in a term neonate 11,12. It is because of this decreased urinary 
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concentrating capacity that normal saline, which is commonly recommended 
as the basic intravenous fluid solution in older children, 13 is not suitable in the 
NICU, as it typically will be hypertonic compared to the baby’s urine and thus 
may lead to hypernatremia . 
The impaired ability of the neonatal and especially premature kidneys to maintain 
electrolyte homeostasis is also reflected in the wider reference range for plasma 
electrolytes. For instance, plasma sodium between 125 and 150 mmol/l are usually 
considered normal in this age group 14. This relative instability is further compounded 
by some factors specific to the transition from intra-to extrauterine life and the early 
neonatal period: 
• Extra-renal water losses are increased due to the greater ratio of surface area 
to body mass, and will be further increased by the use of radiant heaters and 
UV therapy. Moreover, immature skin is more permeable to water, probably 
due to higher expression of water channels (aquaporins)15,16. 
• The composition and distribution of body water changes with gestation: at 23-
weeks, water makes up 90% of body weight, with two thirds in the 
extracellular fluid (ECF) and one third in the intracellular fluid (ICF). At 
term, 75% of body weight is water and this is now roughly equally distributed 
between ECF and ICF, whereas in an adult, water makes up approximately 
60% of body weight with one third in ECF and two thirds in ICF 17,18. Thus, 
there is quite a marked contraction of the ECF in the third trimester and the 
neonatal period, which is reflected in the physiologic weight loss, that 
newborns normally experience. 
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Considering all of these circumstances, it is easy to understand that electrolyte 
abnormalities can occur easily in the NICU. 
 
Dysnatremias 
Abnormalities of plasma sodium are probably the most common electrolyte disorder 
encountered in neonates. Nevertheless, they are associated with serious morbidity, 
including a poorer long-term neurological outcome14. 
There are technical obstacles to accurate measurement of the serum sodium.  Most 
laboratories measure sodium using a so-called indirect ion-selective electrode 4. Using 
this method, the sample is diluted in order to maximize sample volume and minimize 
interference from plasma proteins. The formula used to calculate plasma sodium 
concentration from the activity of sodium ions in the sample assumes that water 
comprises 93% of plasma volume, but this assumption fails in plasma samples with 
abnormal protein or lipid content, the so-called “ion exclusion” effect 19. This leads to 
the well-recognized phenomenon of pseudohyponatremia in lipemic samples or those 
with excess protein content. But the converse is also true: in samples with low protein 
content, the sodium concentration is overestimated, leading to pseudonormo- or 
pseudohypernatremia 20. In one study, hypoproteinemia was present in almost 60% of 
plasma samples obtained in the NICU and led to an overestimation of the sodium 
concentration by >3 mmol/l in about a third of all samples and in some occasions by 
more than 10 mmol/l, when compared to the measurement with a direct ion-selective 
electrode, which is not susceptible to this ion-exclusion effect 21. This needs to be 
considered when assessing a plasma sodium result from a hypoproteinemic neonate 
and it is important to remember that the point-of-care analyzers often present in the 
NICU do not use the indirect method. Thus results from these analyzers are likely to 
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be more accurate in samples with abnormal protein content than those obtained in the 
main laboratory 21. 
 
Hyponatremia 
When faced with a low plasma sodium result, the first consideration should be the 
patient: if the patient is seizing and the sodium is substantially lower than previous 
results, than the result is likely real and emergency treatment with hypertonic saline 
should be instigated. If the patient is stable, there is time for a careful assessment: 
• Is this true or pseudohyponatremia (see ion exclusion effect above)? 
• What is the cause of the hyponatremia?  
 
How to assess the cause of true hyponatremia (see also figure 1)? 
The immediate first question should be:  
• Is hyponatremia due to an excess of water or a deficiency of sodium? 
Excess water is the most common cause. In this case, weight and blood pressure are 
either stable or increased and there is normal skin turgor and peripheral perfusion. Of 
course, due to the special circumstances of the perinatal period, the weight is more 
difficult to interpret. A weight loss of 5-10% of body weight is physiologic and 
expected in the first postnatal days. Thus, hyponatremia associated with this expected 
weight loss and otherwise clinically normal volume status does not indicate 
hypovolemia and salt loss. Once the assessment of water excess versus salt loss has 
been made, biochemical evaluation of the urine can help delineate the etiology. 
 A key point to remember is that kidneys regulate sodium reabsorption to maintain 
volume homeostasis, but not to maintain  a normal sodium concentration. There are 
no sodium or osmosensors in the kidneys. Therefore, with excess water, the kidneys 
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will excrete sodium to restore euvolemia. For this reason, weight and blood pressure 
can be stable and not increased with water excess. Thus, an elevated urine sodium 
does not necessarily indicate primary renal salt loss, but may be the appropriate 
physiologic response to water overload. 
Interpretation of biochemical urinary indices is again more difficult in the NICU. The 
physiologic contraction of the extracellular fluid volume in the first days of life is 
associated with excretion of sodium. Moreover, as discussed above, maximal urinary 
concentration is impaired in neonates. A urine osmolality isotonic to plasma thus may 
reflect appropriate maximal concentration of immature kidneys or may be pathologic. 
Therefore, making clear-cut isolated interpretations of urine biochemistries is difficult 
and sometimes impossible. Biochemical and clinical data (see box 1) need to be 
integrated to generate a reasonable diagnosis. 
 
Treatment of hyponatremia 
Emergency treatment of hyponatremia in an acutely symptomatic child involves 
administration of salt, irrespective of the underlying cause. A commonly used 
protocol is a bolus of 2 ml/kg 3% NaCl, repeated as necessary 22.  
In the asymptomatic child, several options are available: in the case of water excess, 
the simplest treatment is to reduce the volume of water administered. The excess 
volume can be calculated: assuming a total body water content of 75% (this may be 
Box 1: Clinical parameters for the assessment of dysnatremias 
• weight  
• blood pressure 
• skin turgor 
• peripheral perfusion 
• type and volume of administered fluids 
• insensible water losses (radiant warmer? UV therapy?) 
• urine output 
• renal ultrasound 
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higher in premature babies, see above), the excess volume is weight [kg] x 0.75 x 
(130 - observed Na) /130. Thus, a euvolemic 3-kg neonate with a sodium of 120 
would be estimated to have 3 x 0.75 x 10 / 130 = 0.173 l excess water and reduction 
of water administration by this amount over the next 24-48h would be expected to 
normalize plasma sodium to 130 mmol/l over the same time period, assuming that 
other factors, such as insensible water losses and urine output remain unchanged. It is 
clear from this last statement that close observation is important for successful 
management. 
Recently, antagonists for the type 2 vasopressin receptor AVPR2 have been 
introduced for the treatment of patients with hyponatremia due to vasopressin excess 
23. However, no efficacy or toxicity data in neonates currently exist and given the ease 
of control over fluid administration in the NICU and the impaired concentrating 
capacity of neonates, these drugs are unlikely to be used commonly in this setting. 
For those patients presumed to have a sodium deficit, sodium supplementation is the 
correct treatment and the sodium deficit can be calculated similar to the water excess: 
weight [kg] x 0.75 x (130 - observed Na). Thus, a hypovolemic 3-kg neonate with a 
sodium of 120 would be estimated to have 3 x 0.75 x 10 = 7.5 mmol sodium deficit 
and administration of this amount over the next 24-48h would be expected to 
normalize plasma sodium to 130 mmol/l over the same time period, assuming that the 
other factors remain unchanged. In an asymptomatic child, slow correction of the 
plasma sodium concentration is generally advised due to concerns over osmotic 
demyelination, especially in chronic hyponatremia. An increase by not more than 10 
mmol/l/d is generally considered safe 24. 
 
Hypernatremia 
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The basic considerations in hypernatremia are the same as for hyponatremia. The 
sodium can be falsely high due to low protein content of the plasma and this can be 
verified by checking with a different method, not prone to the ion exclusion effect 
(see above). If true, the next question is whether the high sodium reflects a deficiency 
in water or an excess of salt and based on the clinical and biochemical data an 
underlying diagnosis can be made (see Figure 2). As with hyponatremia, the most 
common explanation for an abnormal plasma sodium is a disorder of water, rather 
than sodium, but there are many hidden sources of sodium, mostly from line flushes 
and bronchial lavage with normal saline, or from medications, which may add up 
sufficiently to exceed renal excretory capacity and thus cause hypernatremia 25. 
A deficiency in water can occur for instance when insensible water losses are 
underestimated.  
 
Treatment 
The main concern in the treatment of hypernatremia is the development of cell 
swelling as plasma sodium falls, resulting in cerebral edema. For this reason, a slow 
correction, not exceeding 10 mmol/l/d is generally advised. The same formulas listed 
under hyponatremia (see above) can be used to estimate the water deficit or sodium 
excess and water administration can be increased or sodium administration decreased 
accordingly. 
 
Dyskalemias 
A few key facts on potassium: 
• It is the most abundant intracellular ion and intracellular potassium 
concentration is usually between 100-150 mmol/l  
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• It is a critical component for many cellular functions, including cell growth 
and division, DNA and protein synthesis, as well as for many enzyme and 
transport processes 26  
• Approximately 98% of total body potassium is in the ICF, especially in 
skeletal muscle, and thus only 2% is in the ECF, where it is accessible to 
routine clinical measurements 27  
• The usual normal range in neonates is 4.0-6.5 mmol/l and thus somewhat 
higher than in older children and adults 28,29  
• The kidneys maintain potassium homeostasis by adjusting potassium excretion 
to intake. About 90% of ingested potassium is absorbed and only about 5 – 
10% of this is excreted via extrarenal pathways, mainly the gut, although this 
can increase substantially in renal failure 30  
• Neonates and infants maintain positive potassium balance to allow 
incorporation into cells newly formed during the period of somatic growth 31  
 
Internal potassium balance 
An important concept for the understanding and management of dyskalemia is the so-
called internal potassium balance, which describes the ability of potassium to shift 
between the ICF and ECF 32. Several factors affect this balance, including: 
• Acid-base status, as acidosis leads to a shift out of the cells and vice versa in 
alkalosis 33. A whole range of different transport processes is involved in this 
shift, which results in buffering of the acid-base abnormality by the cells 34. In 
one study, a pH shift by 0.1 led to a change in plasma potassium by 
approximately 0.6 mmol (range 0.2-1.7) 35 
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• Hormones and medications that affect the activity of the cellular Na/K 
ATPase, such as insulin, adrenalin and drugs affecting the sympathetic 
nervous system and digitalis derivatives 36 
Consequently, an important first assessment of dyskalemia is whether it is due to a 
disturbed internal (potassium shift) or external balance (imbalance between intake and 
output). 
 
Hypokalaemia 
Clinical manifestations 
Patients with mild hypokalemia are usually asymptomatic, but symptoms may occur 
with potassium levels <3mmol/l. Symptoms may include muscle weakness, 
constipation and ileus. With severe hypokalemia, rhabdomyolysis, arrhythmias and 
even cardiac or respiratory arrest have been reported 37 38.  
 
Clinical assessment 
As discussed above, an important consideration is whether the derangement reflects a 
change in the internal balance (and total body potassium is unaffected) or the external 
balance (altered intake or excretion). Clinical factors taken into this consideration are 
listed in box 2. 
An important initial consideration is the medication list. Many drugs commonly used 
in the NICU affect the internal potassium balance [e.g. xanthines (theophylline, 
caffeine) and bronchodilators (β2-sympathomimetics)]. Others increase urinary losses 
(e.g. loop diuretics, amphotericin). A list of commonly used medications affecting 
potassium levels is given in table 1. 
 
Bockenhauer and Zieg: Electrolyte disorders 
 13 
 
In addition, there are some rare inherited disorders that can cause hypokalemia in the 
newborn, including neonatal Bartter syndrome (discussed below), congenital adrenal 
hyperplasia (with salt retention), apparent mineralocorticoid excess and congenital 
chloride losing diarrhea. 
In cases with disturbed external potassium balance (potassium loss), biochemical 
analysis of plasma and urine can help distinguish between renal and extrarenal 
potassium loss. Commonly used is the fractional excretion of potassium (FEK) with 
an FEK of >15% usually considered suggestive of renal losses 39. A more specific 
way to assess potassium secretion in the collecting duct (see Figure 4 for the 
molecular basis) is the transtubular potassium gradient TTKG 40 (see also box 3). 
Box 2: Clinical parameters for the assessment of dyskalemias 
• ECG (T-waves, U-waves, QT interval) 
• Acid-base status 
• Plasma biochemistries (associated other electrolyte abnormality, kidney function, 
muscle enzymes in suspected rhabdomyolysis) 
• Potassium intake (concentration in administered fluids and nutrition) 
• Urinary potassium excretion (volume of urine and urinary potassium concentration) 
• Extrarenal potassium losses (stool, NG or other drainage) 
• Medications 
• Renal ultrasound (nephrocalcinosis, obstruction) 
 
Box 3: The transtubular potassium gradient TTKG 
Calculating the TTKG is based on the idea that potassium concentration in the collecting 
duct can change primarily due to two factors: 
1. Secretion of potassium 
2. Extraction of water 
It is calculated as follows: (UK / Uosm) / (PK / Posm) 
With UK and PK = urinary and plasma potassium concentration, respectively and Uosm 
and Posm = urinary and plasma osmolality. 
 
The higher the TTKG, the more potassium is secreted in the collecting duct. A value of <2 
is consistent with little to no secretion. Normal range for term newborns in one study was 
5.65 – 18.22. TTKG in preterm neonates is usually lower, reflecting tubular immaturity 1. 
The TTKG is valid only during antidiuresis. Thus, if Uosm is < Posm, then the TTKG is 
not useful, limiting its applicability in the NICU, given the physiologic concentrating 
defect of neonates. 
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Treatment 
Treatment of hypokalemia depends on the symptoms and the underlying etiology. In 
patients with disturbed internal balance, removal of the underlying cause (e.g. 
discontinuation of medications causing potassium shift) will usually result in 
normalization of the plasma levels within hours. 
In cases with disturbed external potassium balance and a true potassium deficit, 
potassium supplementation is usually commenced, ideally with removal of the 
underlying cause (e.g. discontinuation of medications causing potassium wasting). 
Urgent supplementation, such as infusion of 0.3 mmol/kg of potassium-chloride over 
1 hour is usually only given in cases of severe symptomatic hypokalemia (e.g. serious 
cardiac arrhythmias, respiratory depression). As rapid changes of plasma potassium 
concentration can lead to cardiac arrhythmias in itself, these patients should be 
monitored carefully. It is also important to recognize that potassium supplementation 
in a patient with hypokalemia due to a shift in the internal balance can experience 
rebound hyperkalemia, once the cause for the shift resolves.  
 
Hyperkalemia 
Hyperkalemia is defined as a plasma potassium concentration > 6.5 mmol/l in 
newborns. As with hypokalemia, a key concern is cardiac arrhythmia. In an 
asymptomatic patient, a first consideration should be whether this is true 
hyperkalemia or an artifact from hemolysis due to traumatic phlebotomy  (i.e., from 
squeezing or prolonged application of a tourniquet) 43. An ECG can help assess the 
severity, with peaked T waves indicating true hyperkalemia. 
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Otherwise, the same considerations apply as in hypokalemia: is it a disturbance of the 
internal or external potassium balance? Presence of a metabolic acidosis or 
administration of medications such as digitalis would suggest disturbance of the 
internal balance. If the external balance is affected, assessment of urinary potassium 
excretion (see box 3) can help distinguish between excess administration (FEK and 
TTKG high) and impaired elimination (FEK and TTKG low). An increased potassium 
load can also result from cellular lysis (e.g. after an internal bleed, such as 
gastrointestinal or intraventricular hemorrhage). Premature babies are especially at 
risk of hyperkalemia due to their impaired potassium secretory ability reflecting 
tubular immaturity. Indeed, hyperkalemia is seen in more than 50% of extremely 
premature babies with a birth weight of less than 1000g 44. 
Impaired kidney function is, of course, another important consideration in any patient 
with hyperkalemia. In addition, there are a few rare inherited diseases that can cause 
hyperkalemia, including pseudohypoaldosteronism type 1 (PHA1, discussed below) 
and congenital adrenal hyperplasia (salt-wasting forms). 
 
Treatment 
Hyperkalemia-induced arrhythmias are a medical emergency. Treatment usually 
includes intravenous calcium salts to decrease myocyte excitability. In non-oliguric 
neonates, medications affecting internal potassium balance, including glucose with 
insulin and beta adrenergic agonists appear preferable to rectal exchange resins for the 
treatment of acute hyperkalemia 29. However, these resins are the only choice in 
oliguric neonates for long-term potassium removal apart from dialysis, but obstruction 
and intestinal necrosis have been reported 45 46.  
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Non-acute treatment depends on the underlying etiology. Correction of an underlying 
acidosis or discontinuation of the causative medication (see table 2) is the obvious 
solution in many cases. Administration of loop diuretics can increase renal potassium 
excretion to help eliminate an acute potassium load. 
 
Inherited disorders associated with electrolyte abnormalities 
There are several inherited disorders that can affect electrolytes in the neonatal period, 
but two (Bartter syndrome and PHA1) will be discussed here briefly, as they 
illuminate the underlying renal physiology of renal electrolyte handling, the 
understanding of which is important for any electrolyte disorder. For a more detailed 
discussion of these disorders, the interested reader is referred to more specific reviews 
39,47,48. 
 
Bartter syndrome 
Bartter syndrome is primarily a disorder of salt reabsorption in the thick ascending 
loop of Henle 39. Several genes have been associated with Bartter syndrome, but three 
are typically associated with antenatal presentation (see also figure 3): SLC12A1, 
encoding the target of loop diuretics, the N+-K+-2Cl- cotransporter NKCC2 (Bartter 
syndrome type 1), KCNJ1, encoding the potassium channel ROMK (Bartter syndrome 
type 2) and BSND, encoding the chloride channel subunit Barttin (Bartter syndrome 
type 4). Whilst there is a huge spectrum of clinical severity with each of these types, 
typical antenatal presentation manifests in utero with polyhydramnios, often requiring 
multiple amniocentesis to relieve the fluid load. The polyhydramnios reflects the 
polyuria of the fetus, the high salt content of which can be used diagnostically 49. 
These salt and water losses continue immediately postnatally and may necessitate 
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supplementation of fluid of > 250 ml/kg/d and sodium-chloride of >15 mmol/kg/d 50. 
Associated with the polyuria is typically a hypokalemic metabolic alkalosis. This is 
due to highly elevated renin and aldosterone levels, reflecting the kidneys attempt to 
salvage the salt not reabsorbed in the thick ascending limb by up-regulating sodium 
reabsorption in the collecting duct. As sodium uptake in this segment is balanced by 
potassium and proton secretion (see figure 4), the patient develops hypokalemia and 
metabolic alkalosis. Hypernatremia can also be present due to an often associated 
urinary concentrating defect 51,52. Without adequate supplementation, affected 
neonates may develop severe dehydration and acute kidney injury, resulting in 
hyperkalemia and acidosis and confusing the diagnostic picture. A history of 
polyhydramnios, although rarely due to Bartter syndrome, should nevertheless alert 
the clinician to this diagnostic possibility so that severe dehydration can be avoided.  
Besides fluid and electrolyte supplementation, treatment of Bartter syndrome involves 
non-steroidal anti-inflammatory drugs, such as indomethacin 53. Whilst in some cases, 
this has even been given antenatally, most neonatologists are hesitant to use this drug 
in the neonatal period due to concerns of serious side effects, such as intestinal 
perforation and bleeding 54,55. 
Bartter syndrome type 2 can be an especially challenging diagnosis in the neonatal 
period, as the underlying protein, the potassium channel ROMK, is not only important 
for salt reabsorption in the thick ascending limb, but also for potassium secretion in 
the collecting duct (figures 3 and 4). Thus, these patients typically experience 
hyperkalemia in the first weeks of life, which slowly converts to hypokalemia, as 
other potassium channels start compensating for the lack of ROMK in the collecting 
duct 56. In some cases, patients initially resemble the phenotype of PHA1 (see below) 
with severe hyperkalemia, hyponatremia and acidosis 57. 
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Pseudohypoaldosteronism type 1 (PHA1) 
PHA1 is primarily a disorder of salt reabsorption in the collecting duct, characterized 
by an inability of this segment to respond to aldosterone. We distinguish a recessive 
form, due to loss-of-function mutations in genes encoding the epithelial sodium 
channel ENaC (see Figure 4) from a dominant form, due to loss-of-function mutations 
in the gene encoding the mineralocorticoid receptor. The recessive form is more 
severe and can include extrarenal manifestation, such as cystic fibrosis-like lung 
disease, as well as skin problems, due to expression of ENaC in these organs. The 
dominant form is milder, restricted to the kidney, and often improves spontaneously 
over time 58. For this review, the renal features are of relevance: patients present with 
severe volume depletion, potentially life-threatening hyperkalemia (sometimes >10 
mmol/l), moderate hyponatremia and acidosis. This electrolyte constellation can be 
easily explained by the molecular characteristics of salt transport in the collecting 
duct (figure 4): reabsorption of sodium occurs via ENaC, expressed in the principal 
cells of the collecting duct, but needs to be electrically balanced. This can occur by 
potassium secretion through ROMK, or by proton secretion from the neighboring 
intercalated cells. Thus sodium (i.e. volume) homeostasis is molecularly coupled to 
potassium and acid-base homeostasis and disturbance of one pathway automatically 
affects the others, as well. Hyponatremia occurs from a combination of sodium loss 
and water retention, as hypovolemia leads to vasopressin-mediated urinary 
concentration. 
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Table 1: Medications associated with hypokalemia 
Modified from 37 
Internal balance Renal excretion Extrarenal excretion 
insulin Loop diuretics 
(e.g.furosemide) 
laxatives 
Xanthines (e.g.caffeine, 
theophylline) 
Thiazide diuretics exchange resins (e.g. 
sodium or calcium 
polystyrene sulfate) 
β2-agonists (e.g.adrenalin, 
salbutamol) 
Carbanhydrase 
inhibitors 
(e.g.acetazolamide) 
 
 amphotericin  
 foscarnet  
 cisplatin  
 aminoglycosides  
 mineralocorticoids  
 
 
Table 2: Medications associated with hyperkalemia 
Modified from 59 
Internal balance Impaired Renal 
excretion 
Increased potassium 
load 
Digitalis Angiotensin 
Converting 
Enzyme inhibitors 
and Angiotensin 
receptor blockers 
Penicillin K 
β2-antagonists Non-steroidal 
antiinflammatory 
drugs 
(indomethacin) 
Stored packed red 
blood cells 
Ε-Aminocaproic acid ENaC blocker 
(amiloride, 
triamteren) 
 
 Spironolactone  
 Antifungals (e.g. 
Ketoconazole) 
 
 Calcineurin 
inhibitors 
(e.g.cyclosporine, 
tacrolimus) 
 
 Trimethoprim  
 Heparin  
 Pentamidine  
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Figure 1: Algorithm for the assessment of hyponatremia 
After establishing that the hyponatremia is true and not a measurement artifact, the 
most important step is to determine whether the cause is an excess of water or a 
deficiency of salt. Once that distinction is made, urinary indices can help delineate the 
etiology. 
 
Figure 2: Algorithm for the assessment of hypernatremia 
After establishing that the hypernatremia is true and not a measurement artifact, the 
most important step is to determine whether the cause is a deficiency of water or an 
excess of salt. Once that distinction is made, urinary indices can help delineate the 
etiology. 
 
 
Figure 3: Diagram of an epithelial cell in the thick ascending limb 
Sodium is reabsorbed together with potassium and chloride via the apical transporter 
NKCC2, the target of loop diuretics. Transport is facilitated by the action of the 
basolateral Na/K-ATPase, which creates the electrochemical gradient favoring 
sodium movement into the cell and also provides a basolateral exit for sodium. 
Chloride exits the cell via the basolateral chloride channels CLCKNA and B. 
Function of NKCC2 is critically dependent on the availability of potassium, which is 
ensured through recycling of potassium via the potassium channel ROMK. This 
recycling of potassium across the apical membrane contributes to a lumen-positive 
transepithelial voltage, which enables reabsorption of calcium, magnesium and 
sodium though a paracellular pathway lined by CLDN16 and 19. Modified from 39. 
 
Figure 4: Diagram of a principal cell in the collecting duct 
Sodium is reabsorbed via the epithelial sodium channel ENaC, expressed on the 
apical side. Uptake is facilitated by the action of the basolateral Na/K-ATPase, which 
creates the electrochemical gradient favoring sodium movement into the cell and also 
provides a basolateral exit for sodium. Electrical balance for sodium uptake can be 
provided by potassium secretion through the apical potassium channel ROMK or by 
proton secretion from neighboring intercalated cells (not shown). Thus sodium (i.e. 
volume) homeostasis is molecularly linked with potassium and acid-base homeostasis 
in this nephron segment. Modified from 39. 
 
